Effect of spironolactone on cardiovascular complications associated with type-2 diabetes in rats

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 8, 2013, Pages 441-447

  Patel, B M ^a   Kakadiya, J ^c   Goyal, R K ^b   Mehta, A A ^c  

^a NIRMA UNIVERSITY   (India)

^b AHMEDABAD UNIVERSITY   (India)

^c L M COLLEGE OF PHARMACY   (India)

Author keywords

cardiac hypertrophy; cardiovascular complications; spironolactone; type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; GLUCOSE; INSULIN; LACTATE DEHYDROGENASE; SPIRONOLACTONE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFECT; DYSLIPIDEMIA; FLUID INTAKE; GLUCOSE BLOOD LEVEL; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM CARE; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; TACHYCARDIA; TREATMENT DURATION;

ANIMALS; CARDIOVASCULAR DISEASES; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; FEMALE; HEART; HEMODYNAMICS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; SPIRONOLACTONE; STREPTOZOCIN;

EID: 84884125227     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0033-1345168     Document Type: Article

References (61)

1. Goyal B. R., Solanki N., Goyal R. K. et al. Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. J Cardiovasc Pharmacol: 2009; 54 502 509
2. th January, 2011
3. Gilbert R. E., Jeriuns G., Cooper M. E. Diabetes and hypertension: prognostic and therapeutic considerations. Blood Press: 1995; 4 329 338 (Pubitemid 26019452)
4. Patel B. M., Agarwal S. S., Bhadada S. V. Perindopril protects against streptozotocin induced hyperglycemic myocardial damage/alterations. Human and Experimental Toxicology: 2012; 31 1138 1149
5. Patel B. M., Mehta A. A. The choice of antihypertensive agents in diabetes subjects. Diabetes and Vascular Disease Research: 2013; [Accepted]
6. Goyal B. R., Patel M. M., Bhadada S. V. Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril on diabetes induced cardiovascular complications in type 1 diabetes in rats. International Journal of Diabetes and Metabolism: 2011; 19 11 18
7. Patel B. M., Mehta A. A. Aldosterone And Angiotensin: Role In Diabetes And Cardiovascular Diseases. European Journal of Pharmacology: 2012; 697 1 12
8. Stier C. T. Jr, Chander P. N., Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev: 2002; 10 97 107 (Pubitemid 34246658)
9. Jandeleit-Dahm K. A., Tikellis C., Reid C. M. et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens: 2005; 23 463 473 (Pubitemid 40684700)
10. Barbato J. C., Rashid S., Mulrow P. J. et al. Mechanisms for Aldosterone and Spironolactone-Induced Positive Inotropic Actions in the Rat Heart. Hypertension: 2004; 44 751
11. Nehme J. A., Lacolley P., Labat C. et al. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol: 2005; 39 511 519 (Pubitemid 41133736)
12. Pitt B., Zannad F., Remme W. J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med: 1999; 341 709 717 (Pubitemid 29407370)
13. Tsutamoto T., Wada A., Maeda K. et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol: 2001; 37 1228 1233
14. Goyal B. R., Mehta A. A. Beneficial role of spironolactone, telmisartan and their combination on isoproterenol induced cardiac hypertrophy. Acta Cardiologica January: 2012; 67 203 211
15. Goyal B. R., Mesariya P., Goyal R. K. et al. Effect of telmisartan on cardiovascular complications associated with STZ-diabetic rats. Mol Cell Biochem: 2008; 314 123 131
16. Goyal B. R., Parmar K., Goyal R. K. et al. Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type-2 diabetic rats. Pharmacol Rep: 2011; 63 956 966
17. Beutler E., Duron O., Kelly B. Reduced glutathione estimation. J Lab Clin Med: 1963; 61 882
18. Misra H. P., Frodvich I. The role of superoxide anion autoxidation of epinephrine and a simple method for superoxide dismutase. J Biol Chem: 1984; 247 3170 3175
19. nd edition. New York Academic Press: 1974
20. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal Biochem: 1979; 95 351 358 (Pubitemid 9194347)
21. Portha B., Picon L., Rosselin G. Chemical diabetes in the adult rats as the spontaneous evolution of neonatal diabetes. Diabetologia: 1979; 17 371 377 (Pubitemid 10219170)
22. Bochud M., Nussberger J., Bovet P. et al. Plasma Aldosterone Is Independently Associated With the Metabolic Syndrome. Hypertension: 2006; 48 239 245 (Pubitemid 44309818)
23. Epstein M., Buckalew V., Martinez F. M. et al. Anti-proteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens: 2002; 15 24A Abstract OR-54
24. Goyal B., Mehta A. Diabetic cardiomyopathy: Pathophysiological mechanisms and cardiac dysfuntion. Hum Exp Toxicol: 2012; [Epub ahead of print]
25. Hitomi H., Kiyomoto H., Nishiyama A. et al. Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells. Hypertension: 2007; 50 750 755 (Pubitemid 47442741)
26. Corbould A. Effects of Spironolactone on Glucose Transport and lnterleukin-6 Secretion in Adipose Cells of Women. Horm Metab Res: 2007; 39 915 918
27. Kopprasch S., Pietzsch J., Ansurudeen I. et al. Prediabetic and diabetic in vivo modification of circulating low-density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion. J Endocrinol: 2009; 200 45 52
28. Ostergren J. Renin-angiotensin-system blockade in the prevention of diabetes. Diabetes Res Clin Pract: 2007; 76 S13 S21 (Pubitemid 46501793)
29. Maliukova N. G. Effect of hyperlipidemia on the activity of renin-angiotensin-aldosterone system in patients with chronic cardiac insufficiency. Lik Sprava: 2004; 5-6 29 32
30. Gökmen O., Senöz S., Gülekli B. et al. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol: 1996; 10 249 255 (Pubitemid 26343485)
31. Ridker P. M., Stampfer M. J., Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA: 2001; 285 2481 2485 (Pubitemid 32433842)
32. Pradhan A., Manson J., Rifai N. et al. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA: 2001; 286 327 334 (Pubitemid 32656163)
33. Gilbert K. C., Brown N. J. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes: 2010; 17 199 204
34. Syngle A., Vohra K., Kaur L. et al. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis. Scan J Rheum: 2009; 38 15 22
35. Satoh M., Nakamura M., Akatsu T. et al. C-reactive protein co-expresses with tumor necrosis factor-α in the myocardium in human dilated cardiomyopathy. This article is not included in your organization's subscription. However, you may be able to access this article under your organization's agreement with Elsevier. Eur J Heart Fail: 2005; 7 748 754
36. Godfrey V., Farquharson C. A., Macdonald J. E. et al. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol: 2007; 117 282 284 (Pubitemid 46452773)
37. Huang E., Kuo W., Chen Y. et al. Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clinica himica Acta: 2006; 366 293 298 (Pubitemid 43330998)
38. 12 supplementation attenuates isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. Pharmacol Res: 2002; 46 213 219 (Pubitemid 35300759)
39. Bedrak E., Hammer R., Goldberg S. Plasma enzymes in relation to aldosterone administration and acclimatization in rats. J Appl Physiol: 1967; 22 297 300
40. Mizushige K., Yao L., Noma T. et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation: 2000; 101 899 907 (Pubitemid 30117886)
41. Zannad F., Dousset B., Alla F. Treatment of Congestive Heart Failure; Interfering the Aldosterone-Cardiac Extracellular Matrix Relationship. Hypertension: 2001; 38 1227
42. Guarda E., Myers P., Brilla C. et al. Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc Res: 1993; 27 1004 1008 (Pubitemid 23219518)
43. Delcayre C., Silvestre J. S. Review. Aldosterone and the heart: towards a physiological function? Cardiovasc Res: 1999; 43 7 12 (Pubitemid 29322857)
44. Mill J. G., Milanez Mda C., de Resende M. M. et al. Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol: 2003; 30 739 744 (Pubitemid 37330520)
45. Lacolley P., Safar M. E., Lucet B. et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol: 2001; 37 662 667
46. Nagata K., Obata K., Xu J. et al. Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats. Hypertension: 2006; 47 656
47. Grossman E., Shemesh J., Shamiss A. et al. Left Ventricular Mass in Diabetes. Arch Int Med: 1992; 152 5
48. Okoshi M. P., Yan X., Okoshi K. et al. Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail: 2004; 10 511 518
49. Takeda Y., Yoneda T., Demura M. et al. Cardiac aldosterone production in genetically hypertensive rats. Hypertension: 2000; 36 495 500
50. Tsukashita M., Marui A., Nishina T. et al. Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery. J Thorac Cardiovasc Surg: 2008; 136 58 64
51. Bunag R. D., Tomita T., Saski S. Streptozocin diabetic rats are hypertensive despite reduced hypothalamic responsiveness. Hypertension: 1982; 4 556 565 (Pubitemid 12017367)
52. Baum M. Insulin stimulates volume absorption in the rabbit proximal convoluted tubule. J Clin Invest: 1987; 79 1104 1109 (Pubitemid 17065490)
53. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension: 1994; 24 571 575 (Pubitemid 24337826)
54. Hoffmann J., Grimm W., Menz V. et al. Heart rate variability and baroreflex sensitivity in idiopathic dilated cardiomyopathy. Heart: 2000; 83 531 538
55. Zhang Y., Liu J., Wang Y. et al. Intervention of spironolactone on heart rate variability and its circardian rhythm in patients with heart failure. J Chin Clin Med: 2006; 1 264 267
56. Zhang M., Xu Y. J., Saini H. K. et al. Pentoxifylline attenuates cardiac dysfunction and reduces TNF-α level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol: 2005; 289 H832 H839 (Pubitemid 41129401)
57. Quinkler M., Zehnder D., Eardley K. S. et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation: 2005; 112 1435 1443 (Pubitemid 41291769)
58. Han S., Kim C., Kim H. et al. Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic Rats. J Am Soc Nephrol: 2006; 17 1362 1372 (Pubitemid 43673416)
59. Siwik D., Fagano P. J., Colucci W. S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol: 2001; 280 C53 C60
60. Haffner S. M., Agil A., Mykkanen L. et al. Plasma oxidizability in subjects with normal glucose tolerance and NIDDM. Diabetes Care: 1995; 18 646 653
61. Zhao W., Ahokas R. A., Weber K. T. et al. II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol: 2006; 291 H336 H343